Hisashi Hidaka

机构：Kitasato University · ORCID：0000-0002-4151-5663

发表论文 380 篇 · 总被引 16867 次 · h-index 63

代表论文

• Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial (2023 · The Lancet · 被引 516)
• Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation (2024 · Journal of Gastroenterology · 被引 24)
• Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma (2024 · Hepatology International · 被引 11)
• Guidelines for the diagnosis and treatment of idiopathic portal hypertension, extrahepatic portal obstruction, and Budd–Chiari syndrome in Japan (2024 · Hepatology Research · 被引 5)
• Progression pattern and post‐progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma (2024 · Liver International · 被引 5)
• Quantification of Streptococcus salivarius using the digital polymerase chain reaction as a liver fibrosis marker (2025 · World Journal of Hepatology · 被引 2)